CEL-SCI EBITDA par action

Que fait CEL-SCI ? CEL-SCI Corp develops immunotherapies targeting cancer and infectious diseases, focusing on Multikine for head and neck cancers and anal warts in HIV/HPV co-infected patients, and L.E.A.P.S. technology for influenza and rheumatoid arthritis treatments. The company generates revenue through research and development services, with products like LEAPS-H1N1-DC and CEL-2000/CEL-4000 in clinical development. Its primary customers are pharmaceutical partners and research institutions seeking novel therapeutic solutions. The firm operates within the biotechnology sector, emphasizing immune system activation for disease treatment. Multikine and L.E.A.P.S. therapies represent CEL-SCI's core product pipeline, with Multikine targeting head and neck cancers and cervical dysplasia, while L.E.A.P.S. focuses on pandemic influenza and rheumatoid arthritis. The company monetizes its R&D efforts by advancing these therapies through clinical trials, aiming for partnerships with larger pharmaceutical firms for commercialization. Its segment is defined by the development of investigational drugs and vaccines, with no current commercial products generating direct revenue. CEL-SCI's revenue model relies on securing funding for clinical trials and potential future licensing agreements. The company's focus on immune-based therapies for unmet medical needs attracts interest from biotech investors and collaborative partners. Its product candidates, including LEAPS-H1N1-DC and CEL-2000, are positioned for development into marketable treatments, though no sales have occurred yet. CEL-SCI est l'une des entreprises les plus populaires sur Eulerpool.